ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0863

Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study

Chi Chiu Mok1, Ling Yin Ho2, Kar Li Chan3, Sau Mei TSE2 and Chi Hung To4, 1Tuen Mun Hospital, Hong Kong, China, 2Tuen Mun Hospital, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Hong Kong, 4Pok Oi Hospital, Hong Kong, Hong Kong

Meeting: ACR Convergence 2021

Keywords: biomarker, Cardiovascular, Prognosis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: To study the predictive value of serum PCSK9 level on cardiovascular complications in Chinese patients with systemic lupus erythematosus (SLE).

Methods: Consecutive patients who fulfilled ≥4 1997 ACR criteria for SLE and consented for a biomarker study between 2009 and 2012 were included. Stored serum samples from these patients were assayed for PCSK9 using a commercial ELISA kit. New ischemic vascular events in these patients during follow-up were evaluated. ROC analysis was performed to adopt the best cut-off value of PCSK9 for the prediction of a new vascular event. Patients were divided into two groups according to this cut-off value. The cumulative incidence of new vascular event and mortality over time was studied by Kaplan-Meier’s analysis and compared between the high and low PCSK9 subgroups. Cox regression was performed to study the effect of the PCSK9 subgroups on new vascular events and mortality, adjusted for other confounding factors.

Results: 539 SLE patients were studied (93% women, age 41.9±14.0 years; disease duration 106±90.4 months at entry). The mean PCSK level at baseline was 265±158ng/ml and a cut-off of 243.25ng/ml best predicted a new vascular event by the maximum Youden’s index (ROC analysis: AUC 0.63[0.51-0.74]; sensitivity 69%; specificity 61%). 220 SLE patients had baseline PCSK9 level of ≥243.25ng/ml (high PCSK9) and 319 patients had level below 243.25ng/ml (low PCSK9). No significant difference in SLE manifestations and autoantibody profile was observed between the high and low PCSK9 groups except the former had a significantly higher prevalence of lupus nephritis. 31 new vascular events (13 ischemic stroke, 13 acute coronary syndrome and 5 peripheral vascular disease) developed in 29 patients over a mean follow-up of 91.3±18.6 months. Patients with a new vascular event had a significantly higher baseline PCSK9 level than those without (350±225 vs 260±153ng.ml; p=0.02). The cumulative incidence of a first vascular event at 5 years from study entry was 7.8% in the high PCSK9 group and 1.9% in the low PCSK9 group (log rank test; p=0.003, univariate hazard ratio [HR] 3.08[1.39-6.80]). At last follow-up, 40 patients succumbed (10 due to vascular event [vascular death]). Kaplan-Meier’s analysis showed that the high PCSK9 group had a significant higher cumulative risk of all-cause mortality (log rank test p=0.003; HR2.68[1.39-5.14]) and vascular mortality (log rank test p=0.002; HR12.4[1.56-98.4]) over time than the low PCSK9 group. Cox regression analyses showed that high PCSK9 was significantly associated with new vascular events (HR2.56[1.10-5.99]; p=0.03) independent of age, sex, SLE duration, diabetes mellitus, hypertension, body mass index, atherogenic index, smoking, antiphospholipid antibody, past history of vascular events, and the use of statins, aspirin, hydroxychloroquine, prednisolone, mycophenolate mofetil, azathioprine and the calcineurin inhibitors at study entry.

Conclusion: A higher serum PCSK9 level is a strong risk factor for ischemic vascular events in patients with SLE, which is independent of age, sex, traditional atherosclerotic risk factors, antiphospholipid antibody and the use of statins and immunosuppressive medications.


Disclosures: C. Mok, None; L. Ho, None; K. Chan, None; S. TSE, None; C. To, None.

To cite this abstract in AMA style:

Mok C, Ho L, Chan K, TSE S, To C. Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/serum-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-and-cardiovascular-risk-in-systemic-lupus-erythematosus-a-longitudinal-cohort-study/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-and-cardiovascular-risk-in-systemic-lupus-erythematosus-a-longitudinal-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences